The first gene-edited babies were born in 2018, their creator went to prison and emerged running a new lab, and the regulatory vacuum that made it possible has not been filled.
UpTrust ranks replies so the ones that help each side understand the other rise. Sign up ›
Vertex priced Casgevy at $2.2 million per patient. The disease: sickle cell. The patients: Nigeria, DRC, India, Tanzania. The Nobel: Stockholm. The patent: Boston. The patients are in Kano.
We have seen this. Antiretrovirals at $10,000 per year while millions died, until Indian generics broke the monopoly and the price fell to $350. COVID vaccines developed with public funding, distributed first to countries that could afford advance purchase agreements. Every medical technology arrives in the Global South one generation after it becomes routine in the North.
The governance debate is being held in the wrong rooms. Nuffield is in London. WHO advisory meets in Geneva. National Academies in Washington. When the discuss permissibility, African and South Asian voices are advisory at best. We are consulted. We are not deciding. The ethical framework is being written by the same civilization that patented the technology, and the consultation process is sophisticated enough to look inclusive without transferring actual power.
The say move faster. Faster for whom? If germline editing arrives in 2030, it arrives in Boston, London, and Singapore — not Lagos, Dhaka, or Lima. Not because the technology is expensive but because the IP regimes and clinical infrastructure channel innovation through markets that can pay. Democratizing technology while maintaining patent monopolies is a contradiction nobody has resolved.
What we want is not complicated. Technology transfer provisions. Compulsory licensing for diseases that disproportionately affect us. Regulatory infrastructure funded as part of any moratorium. A governance body headquartered somewhere that is not Geneva.
Where we concede ground: We have not built the regulatory capacity we demand sovereignty to exercise.
What would change our mind: An international body with binding authority, majority Global South representation, mandatory tech transfer, and enforcement power.
Log in to trust or distrust this view.
Log in to reply, or to ask someone to.
AI Disclosure: These views were generated by AI, prompt engineered by the UpTrust team to give a better snapshot of the state of global sensemaking on this topic, and reference as much UpTrust user content as possible. As UpTrust grows, these syntheses will be generated entirely from our content.